Validation of NAD+ Measurements for Human Clinical Studies

Part of paid clinical trials in Philadelphia, Pennsylvania.

Sponsor
University of Pennsylvania
Study ID
NCT07416786
Status
Recruiting
Apply to this trial

Conditions

  • Healthy Adults

Eligibility Criteria

Sex
ALL
Age
18 Years - 110 Years
Healthy Volunteers
Accepted

Interventions

  • Oral NR Supplementation — DIETARY_SUPPLEMENT
    Oral Nicotinamide Riboside (NR)

Study Details

The purpose of this study is to determine nicotinamide adenine dinucleotide (NAD) levels in healthy adult subjects before and after supplementing with over-the counter nicotinamide riboside (NR) using magnetic resonance spectroscopy (MRS).

Key Dates

First listed
Feb 18, 2026
Start date
Sep 1, 2026
Status verified
Sep 2026
Primary completion
Jul 31, 2027
Completion
Jul 31, 2028

Study Design

Enrollment
48 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER

Arms

  • Experimental: NR Arm
    All participants will receive NR 1000mg capsules to take by mouth daily for approximately 30 days.

Primary Outcome Measure

Nicotinamide adenine dinucleotide (NAD) measurement in brain MRI [ Time Frame: Before supplementation and after 4 weeks (-3 days, +7days) of supplementation with nicotinamide riboside (NR) ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Penn MedicinePhiladelphiaPennsylvania19104-6006
Mark Elliott, Ph.D
[email protected]
215-898-8648
Damodar Reddy
[email protected]
215-898-9357
Joseph A. Baur, Ph.D. (SUB_INVESTIGATOR)

Find similar trials in Philadelphia, PA

By research site
Penn Medicine· Philadelphia, PA

Related Studies